Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia

The management of relapsed or refractory acute myeloid leukemia (AML) continues to be therapeutically challenging. Non-toxic immunotherapy approaches are needed to provide long-term anti-leukemic effects. The goal of this study was to determine whether activated T cells (ATCs) armed with bispecific...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubicka, Ewa, Lum, Lawrence G., Huang, Manley, Thakur, Archana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663847/
https://www.ncbi.nlm.nih.gov/pubmed/36389764
http://dx.doi.org/10.3389/fimmu.2022.899468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663847/
https://www.ncbi.nlm.nih.gov/pubmed/36389764
http://dx.doi.org/10.3389/fimmu.2022.899468

Ejemplares similares